Note N - Subsequent Events

6 Months Ended

Jun. 30, 2024

Notes to Financial Statements

Subsequent Events [Text Block]

N. Subsequent Events

The Company evaluated events and transactions occurring subsequent to June 30, 2024, through August 13, 2024, the date the accompanying unaudited condensed consolidated financial statements were issued. During this period, other than the August 2024 Offering and the related entry into the Underwriting Agreement, the entry into the Equity Distribution Agreement, the Genetic Metabolic Diseases Advisory Committee meeting, and receipt of the first round of arimoclomol labeling comments from the FDA, all of which are disclosed in Note A, there were no subsequent events that required recognition in the accompanying unaudited condensed consolidated financial statements, nor were there any additional non-recognized subsequent events that required disclosure.